BRUSSELS (Reuters) - Belgian biotechnology group Galapagos is testing a new class of antibiotics that could be used to treat bacterial infections that have become resistant to other forms of medication.
The group said on Monday that in laboratory tests its new candidate drug, CAM 1, showed better results than traditional antibiotics against the bacteria causing MRSA, a life threatening disease sometimes contracted by hospital patients.
Galapagos said it hoped to enter clinical tests for the drug, which it fully owned, in 2014.
Copyright (2012) Thomson Reuters. Click for restrictions
Advertisement
0 comments
- Get Livefyre
- FAQ
Newest | Oldest
